adairАллергология и Иммунология в ПедиатрииAllergology and Immunology in Paediatrics2500-11752712-7958Ассоциация детских аллергологов и иммунологов России10.53529/2500-1175-2024-2-9-17adair-137Research ArticleОБЗОРREVIEWЛокальные нежелательные реакции при проведении сублингвальной аллерген-специфической иммунотерапии и патогенетически обоснованные методы их коррекции (обзорная статья)Local side effects during sublingual allergen-specific immunotherapy and pathogenetically based methods for their correction (Review)https://orcid.org/0000-0003-0837-1538ЗакурскаяВ. Я.ZakurskayaV. Ya.

Закурская Вита Яковлевна — ассистент кафедры клинической иммунологии и аллергологии ФГБОУ ВО РостГМУ Минздрава России.

344022, Ростов-на-Дону, пер. Нахичеванский, д. 29

Vita Ya. Zakurskaya — assistant of the Clinical Immunology and Allergology Chair, Rostov State Medical University of Russia.

344022, Rostov-on-Don, 29, Nakhichevansky lane

vias.92@mail.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Ростовский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияRostov State Medical University of the Ministry of Health of the Russian FederationRussian Federation20242306202402917Copyright © Закурская В.Я., 20242024Закурская В.Я.Zakurskaya V.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://adair.elpub.ru/jour/article/view/137Введение

Введение. Изучение вопросов эффективности и безопасности аллерген-специфической иммунотерапии сохраняет свою актуальность в связи с появлением персонифицированного подхода в аллергологии и новых лекарственных форм. Нежелательные реакции при проведении сублингвальной аллерген-специфической иммунотерапии являются ведущей причиной прекращения лечения. Понимание механизмов развития побочных эффектов и знание способов их преодоления позволяет достичь лучшей переносимости аллерген-специфической иммунотерапии и сохранить комплаенс пациента.

Цель обзора

Цель обзора: объединить имеющиеся литературные данные о частоте, характере, патогенетических основах нежелательных явлений при проведении сублингвальной аллерген-специфической иммунотерапии и рассмотреть варианты их профилактики и лечения.

Introduction. The study of the effectiveness and safety of allergen-specific immunotherapy remains relevant due to the emergence of a personalized approach in allergology and new dosage forms. Adverse reactions during sublingual allergen-specific immunotherapy are the leading reason of treatment discontinuation. Understanding the mechanisms of side effects and knowing how to overcome them allows us to achieve better tolerability of allergen-specific immunotherapy and maintain patient compliance.

The aim of the review is to combine the available literature data on the frequency, nature, and pathogenetic basis of adverse events during sublingual allergen-specific immunotherapy and to consider options for their prevention and treatment.

аллерген-специфическая иммунотерапияСЛИТнежелательные реакциипобочные эффектыallergen-specific immunotherapySLITadverse reactionsside effectsReferencesJutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma. Allergy. 2020; 75 (8): 2050–2058. https://doi.org/10.1111/all.14240.Jutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma. Allergy. 2020; 75 (8): 2050–2058. https://doi.org/10.1111/all.14240.Балаболкин ИИ. Поллиноз у детей и подростков: современные аспекты патогенеза и тенденции в терапии. Аллергология и иммунология в педиатрии. 2020; 62 (3): 6–14. https://doi.org/10.24411/2500-1175-2020-00001.Balabolkin II. Pollinoz u detei i podrostkov: sovremennye aspekty patogeneza i tendentsii v terapii. Allergologiya i immunologiya v pediatrii. 2020; 62 (3): 6–14. (In Russ.) https://doi.org/10.24411/2500-1175-2020-00001.Schmitt J, Schwarz K, Stadler E, Wüstenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study. J Allergy Clin Immunol. 2015 Dec; 136 (6): 1511–1516. https://doi.org/0.1016/j.jaci.2015.07.038.Schmitt J, Schwarz K, Stadler E, Wüstenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study. J Allergy Clin Immunol. 2015 Dec; 136 (6): 1511–1516. https://doi.org/0.1016/j.jaci.2015.07.038.Van der Borght K, Brimnes J, Haspeslagh E, et al. Sublingual allergen immunotherapy prevents house dust mite inhalant type 2 immunity through dendritic cell-mediated induction of Foxp3+ regulatory T cells. Mucosal Immunology. 2024 Apr. https://doi.org/10.1016/j.mucimm.2024.03.012.Van der Borght K, Brimnes J, Haspeslagh E, et al. Sublingual allergen immunotherapy prevents house dust mite inhalant type 2 immunity through dendritic cell-mediated induction of Foxp3+ regulatory T cells. Mucosal Immunology. 2024 Apr. https://doi.org/10.1016/j.mucimm.2024.03.012.Incorvaia C, Ridolo E, Bagnasco D, Scurati S, Canonica GW. Personalized medicine and allergen immunotherapy: the beginning of a new era. Clin Mol Allergy. 2021 Jul 7; 19 (1): 10. https://doi.org/10.1186/s12948-021-00150-z.Incorvaia C, Ridolo E, Bagnasco D, Scurati S, Canonica GW. Personalized medicine and allergen immunotherapy: the beginning of a new era. Clin Mol Allergy. 2021 Jul 7; 19 (1): 10. https://doi.org/10.1186/s12948-021-00150-z.Yamamoto T, Ohashi-Doi K, Matsuhara H, Verhoog L, Lindholm M, Lawton S, et al. Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets. Curr Ther Res Clin Exp. 2022; 96: 100678. https://doi.org/10.1016/j.curtheres.2022.100678.Yamamoto T, Ohashi-Doi K, Matsuhara H, Verhoog L, Lindholm M, Lawton S, et al. Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets. Curr Ther Res Clin Exp. 2022; 96: 100678. https://doi.org/10.1016/j.curtheres.2022.100678.Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm. 2011 Jun;61 (2): 117–139. https://doi.org/10.2478/v10007-011-0020-8.Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm. 2011 Jun;61 (2): 117–139. https://doi.org/10.2478/v10007-011-0020-8.Блынская ЕВ, Тишков СВ, Алексеев КВ, Минаев СВ, Марахова АИ. Особенности создания методом лиофилизации таблеток, диспергируемых в полости рта. Фармация. 2019; 68 (2): 17–23. https://doi.org/10/29296/25419218-2019-02-03.Blynskaya EV, Tishkov SV, Alekseev KV, Minaev SV, Marakhova AI. Features of the design of freeze-dried orally disintegrating tablets. Farmatsiya (Pharmacy). 2019; 68 (2): 17–23. (In Russ.) https://doi.org/10/29296/25419218-2019-02-03.Литовкина АО. Сто десять лет АСИТ: настоящее и будущее. Вестник аллерголога-иммунолога. 2021; 01 (01): 4–5.Litovkina AO. Sto desyat’ let ASIT: nastoyashchee i budushchee. Vestnik allergologa-immunologa. 2021; 01 (01): 4–5. (In Russ.)Casale TB, Cox LS, Wahn U, Golden DBK, Bons B, Didier A. Safety Review of 5-Grass Pollen Tablet from Pooled Data of Clinical Trials. J Allergy Clin Immunol Pract. 2017; 5: 1717–1727 e1711.Casale TB, Cox LS, Wahn U, Golden DBK, Bons B, Didier A. Safety Review of 5-Grass Pollen Tablet from Pooled Data of Clinical Trials. J Allergy Clin Immunol Pract. 2017; 5: 1717–1727 e1711.Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014; 7 (1): 6. https://doi.org/10.1186/1939-4551-7-6.Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014; 7 (1): 6. https://doi.org/10.1186/1939-4551-7-6.Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006 May; 117 (5): 1021–1035. https://doi.org/10.1016/j.jaci.2006.02.040.Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006 May; 117 (5): 1021–1035. https://doi.org/10.1016/j.jaci.2006.02.040.Belsito DV. The diagnostic evaluation, treatment, and prevention of allergic contact dermatitis in the new millennium. J Allergy Clin Immunol. 2000; 105 (3): 409–420. https://doi.org/10.1067/mai.2000.104937.Belsito DV. The diagnostic evaluation, treatment, and prevention of allergic contact dermatitis in the new millennium. J Allergy Clin Immunol. 2000; 105 (3): 409–420. https://doi.org/10.1067/mai.2000.104937.Bakula A, Lugović-Mihić L, Situm M, Turcin J, Sinković A. Contact allergy in the mouth: diversity of clinical presentations and diagnosis of common allergens relevant to dental practice. Acta Clin Croat. 2011; 50 (4): 553–561.Bakula A, Lugović-Mihić L, Situm M, Turcin J, Sinković A. Contact allergy in the mouth: diversity of clinical presentations and diagnosis of common allergens relevant to dental practice. Acta Clin Croat. 2011; 50 (4): 553–561.Pitsios C, Rossi CM, Terreehorst I, et al. Eosinophilic esophagitis as a side-effect of allergen immunotherapy: protocol for a systematic review and meta-analysis. Eur Ann Allergy Clin Immunol. 2024; 56 (1): 4–8. https://doi.org/10.23822/EurAnnA-CI.1764-1489.311.Pitsios C, Rossi CM, Terreehorst I, et al. Eosinophilic esophagitis as a side-effect of allergen immunotherapy: protocol for a systematic review and meta-analysis. Eur Ann Allergy Clin Immunol. 2024; 56 (1): 4–8. https://doi.org/10.23822/EurAnnA-CI.1764-1489.311.Miehlke S, Alpan O, Schröder S, Straumann A. Induction of eosinophilic esophagitis by sublingual pollen immunotherapy. Case Rep Gastroenterol. 2013; 7 (3): 363–368. https://doi.org/10.1159/000355161.Miehlke S, Alpan O, Schröder S, Straumann A. Induction of eosinophilic esophagitis by sublingual pollen immunotherapy. Case Rep Gastroenterol. 2013; 7 (3): 363–368. https://doi.org/10.1159/000355161.Kawashima K, Ishihara S, Masuhara M, et al. Development of eosinophilic esophagitis following sublingual immunotherapy with cedar pollen extract: A case report. Allergol Int. 2018; 67 (4): 515–517. https://doi.org/10.1016/j.alit.2018.03.003.Kawashima K, Ishihara S, Masuhara M, et al. Development of eosinophilic esophagitis following sublingual immunotherapy with cedar pollen extract: A case report. Allergol Int. 2018; 67 (4): 515–517. https://doi.org/10.1016/j.alit.2018.03.003.Petroni D, Spergel JM. Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy. Ann Allergy Asthma Immunol. 2018; 120 (3): 237–240.e4. https://doi.org/10.1016/j.anai.2017.11.016.Petroni D, Spergel JM. Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy. Ann Allergy Asthma Immunol. 2018; 120 (3): 237–240.e4. https://doi.org/10.1016/j.anai.2017.11.016.Боков ДО, Смирнов ВВ. Совершенствование методов стандартизации экстрактов лечебных аллергенов: от PNU до LC-MS. Иммунопатология, аллергология, инфектология. 2013; 4: 31–41. https://doi.org/10.14427/jipai.2013.4.31.Bokov DO, Smirnov VV. Sovershenstvovanie metodov standartizatsii ekstraktov lechebnykh allergenov: ot PNU do LC-MS. Immunopatologiya, allergologiya, infektologiya. 2013; 4:31–41. (In Russ.) https://doi.org/10.14427/jipai.2013.4.31.Невская ЛВ, Лавренчик ЕИ, Жданова МЮ, Фадейкина ОВ, Капитанова ВК. Международный опыт стандартизации препаратов аллергенов. БИО-препараты. Профилактика, диагностика, лечение. 2017; 4 (64): 222–229.Nevskaya LV, Lavrenchik EI, Zhdanova MYU, Fadeikina OV, Kapitanova VK. Mezhdunarodnyi opyt standartizatsii preparatov-allergenov. BIO-preparaty. Profilaktika, diagnostika, lechenie. 2017; 4 (64): 222–229. (In Russ.)Asllani J, Mitsias D, Konstantinou G, et al. The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project. Clin Transl Allergy. 2023; 13 (6): e12266. https://doi.org/10.1002/clt2.12266.Asllani J, Mitsias D, Konstantinou G, et al. The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project. Clin Transl Allergy. 2023; 13 (6): e12266. https://doi.org/10.1002/clt2.12266.Nolte H, Calderon MA, Bernstein DI, et al. Anaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets. J Allergy Clin Immunol Pract. 2024; 12 (1): 85–95.e4. https://doi.org/10.1016/j.jaip.2023.11.011.Nolte H, Calderon MA, Bernstein DI, et al. Anaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets. J Allergy Clin Immunol Pract. 2024; 12 (1): 85–95.e4. https://doi.org/10.1016/j.jaip.2023.11.011.Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012; 67 (3): 302–311. https://doi.org/10.1111/j.1398-9995.2011.02761.x.Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012; 67 (3): 302–311. https://doi.org/10.1111/j.1398-9995.2011.02761.x.Lin SY, Azar A, Suarez-Cuervo C, et al. Role of sublingual immunotherapy in the treatment of asthma: An updated systematic review. Int Forum Allergy Rhinol. 2018; 8 (9): 982–992. https://doi.org/10.1002/alr.22152.Lin SY, Azar A, Suarez-Cuervo C, et al. Role of sublingual immunotherapy in the treatment of asthma: An updated systematic review. Int Forum Allergy Rhinol. 2018; 8 (9): 982–992. https://doi.org/10.1002/alr.22152.Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010; 2010 (12): CD002893. doi:10.1002/14651858.CD002893.pub2.Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010; 2010 (12): CD002893. doi:10.1002/14651858.CD002893.pub2.Гущин ИС. Устранение неизбежности аллергического ответа. Пульмонология. 2010; (4): 23–33. https://doi.org/10.18093/0869-0189-2010-4-23-33.Gushchin IS. Ustranenie neizbezhnosti allergicheskogo otveta. Pul’monologiya. 2010; (4): 23–33. (In Russ.) https://doi.org/10.18093/0869-0189-2010-4-23-33.Novak N, Allam JP. Mucosal dendritic cells in allergy and immunotherapy. Allergy. 2011 Jul; 66 Suppl 95: 22–24. https://doi.org/10.1111/j.1398-9995.2011.02626.x. PMID: 21668846.Novak N, Allam JP. Mucosal dendritic cells in allergy and immunotherapy. Allergy. 2011 Jul; 66 Suppl 95: 22–24. https://doi.org/10.1111/j.1398-9995.2011.02626.x. PMID: 21668846.Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, Novak N. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy. 2008 Jun; 63 (6): 720–727. https://doi.org/10.1111/j.1398-9995.2007.01611.x. PMID: 18445186.Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, Novak N. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy. 2008 Jun; 63 (6): 720–727. https://doi.org/10.1111/j.1398-9995.2007.01611.x. PMID: 18445186.Ricca V, Landi M, Ferrero P, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2000; 105 (1 Pt 1): 54–57. https://doi.org/10.1016/s0091-6749(00)90177-5.Ricca V, Landi M, Ferrero P, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2000; 105 (1 Pt 1): 54–57. https://doi.org/10.1016/s0091-6749(00)90177-5.Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update [published correction appears in J Allergy Clin Immunol. 2011 Mar; 127 (3): 840]. J Allergy Clin Immunol. 2011; 127 (1 Suppl): S1–S55. https://doi.org/10.1016/j.jaci.2010.09.034.Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update [published correction appears in J Allergy Clin Immunol. 2011 Mar; 127 (3): 840]. J Allergy Clin Immunol. 2011; 127 (1 Suppl): S1–S55. https://doi.org/10.1016/j.jaci.2010.09.034.Passalacqua G, Villa G, Altrinetti V, Falagiani P, Canonica GW, Mariani G, Bagnasco M. Sublingual swallow or spit? Allergy. 2001 Jun; 56 (6): 578. https://doi.org/10.1034/j.1398-9995.2001.056006578.x. PMID: 11421908.Passalacqua G, Villa G, Altrinetti V, Falagiani P, Canonica GW, Mariani G, Bagnasco M. Sublingual swallow or spit? Allergy. 2001 Jun; 56 (6): 578. https://doi.org/10.1034/j.1398-9995.2001.056006578.x. PMID: 11421908.Федеральные клинические рекомендации по проведению аллерген-специфической иммунотерапии. — M: Российская ассоциация аллергологов и клинических иммунологов, 2013. — 14 c.Federal’nye klinicheskie rekomendatsii po provedeniyu allergen-spetsificheskoy immunoterapii. Moscow, Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov, 2013. 14 p. (In Russ.)Карева ЕН. Выбор антигистаминного препарата: взгляд фармаколога. Российский Медицинский Журнал. 2016; 12: 811–816.Kareva EN. Vybor antigistaminnogo preparata: vzglyad farmakologa. RMZH. 2016; 12: 811–816. (In Russ.)Tarzi M, Klunker S, Texier C, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006; (36): 465–474. https://doi.org/10.1111/j.13652222.2006.02469.x.Tarzi M, Klunker S, Texier C, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006; (36): 465–474. https://doi.org/10.1111/j.13652222.2006.02469.x.Alexander C, Ying S, Kay A, Larche M. Fel d 1-derived T-cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon-gamma + T-helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy. 2005; (35): 52–58. https://doi.org/10.1111/j.13652222.2005.02143.x.Alexander C, Ying S, Kay A, Larche M. Fel d 1-derived T-cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon-gamma + T-helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy. 2005; (35): 52–58. https://doi.org/10.1111/j.13652222.2005.02143.x.Турчина МС, Карасева ЗВ. Синдром низкой резистентности к гистамину: причина или следствие патологии ЖКТ? Экспериментальная и клиническая гастроэнтерология. 2020; (7): 152–157. https://doi.org/10.31146/1682-8658-ecg-179-7-152-157.Turchina MS, Karaseva ZV. Sindrom nizkoi rezistentnosti k gistaminu: prichina ili sledstvie patologii ZHKT? Ehksperimental’naya i klinicheskaya gastroehnterologiya. 2020; (7):152–157. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-179-7-152-157.Федеральные клинические рекомендации по диагностике и лечению крапивницы. — М.: Российская ассоциация аллергологов и клинических иммунологов, 2023.Federal’nye klinicheskie rekomendatsii po diagnostike I lecheniyu krapivnitsy. Moscow, Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov, 2023. (In Russ.)Каххарова ДЖ, Даминова НР, Нуруллаева ИР, Ганиев ФЗ, Махкамбаев АМ. Аллергический контактный стоматит, маскирующийся под афтозный стоматит. Universum: медицина и фармакология. 2024; 1 (106): 13–16.Kakhkharova DZH, Daminova NR, Nurullaeva IR, Ganiev FZ, Makhkambaev AM. Allergicheskii kontaktnyi stomatit, maskiruyushchiisya pod aftoznyi stomatit. Universum: meditsina i farmakologiya. 2024; 1 (106): 13–16. (In Russ.)Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol. 2009; 158 (3): 260–271. https://doi.org/10.1111/j.1365-2249.2009.04017.x.Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol. 2009; 158 (3): 260–271. https://doi.org/10.1111/j.1365-2249.2009.04017.x.

The authors declare that there are no conflicts of interest present.